Updates on AHPA activities and resources delivered to your inbox. Subscribe today!
Webinar presenters will address different approaches to sustainability self-assessment, discuss various sustainability standards, and how to create realistic science based targets, and present examples that will help companies of all sizes plan and execute meaningful self-assessments.
AHPA continues to expand and update the online Botanical Safety Handbook 2nd ed. to provide the herbal industry with comprehensive safety information on over 500 species of herbs from clinical trials, pharmacological and toxicological studies, medical case reports, and historical texts.
It is with profound sadness that we announce the passing of our dear colleague and friend Tony Hayes. Tony was a producer and marketer of North American wildcrafted herbs for almost 50 years. He began his career in 1973 as an herb buyer for Lowe Fur and Herb of North Wilkesboro, then in 1981 went to work for Wilcox Drug Company in Boone, North Carolina. In 2000 he and his wife Sandy started their own business, Ridge Runner Trading Company.
The July 2020 AHPA Report includes AHPA goes virtual, postal service funding request, sustainability webinar on July 22, updated CA Prop 65 guidance, revised CITES primer, FTC proposed rule for 'Made in the USA,' and more.
Webinar presenters explain ways to ensure your marketing claims for herbal immune support products are substantiated, truthful and not misleading. Industry experts review several methods they’ve used to ensure their dietary supplement product claims are well substantiated, including: randomized, controlled clinical trials on a well-known elderberry product; in vitro testing to support the legitimacy of the product; and the relevance of use and training in substantiating the effectiveness of traditional Chinese herbal formulations.
Since the first week of March, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have been issuing warning letters alleging that marketers promoted a wide variety of products with claims to prevent, treat, mitigate, diagnose or cure COVID-19.
AHPA has analyzed 135 COVID-19 related warning letters issued by either FDA or FTC or by the agencies jointly between March 6, 2020, and May 11, 2020, and made available in each agency’s coronavirus information center as of May 15, 2020.
I am reaching out today to let you know that all AHPA activities normally held as in-person meetings will instead be produced as virtual events, webinars or teleconferences for the balance of 2020.
This free webinar provides practical information on how best to resume post-quarantine business operations while protecting your workforce. Learn what personal protective equipment and workspace adaptations should be implemented and how to manage ongoing business risks and liabilities. Additionally, hear from experts about how to be proactive and search for, and then correct, workplace conditions that could increase risk of COVID-19 infections.